Sathekge, Mike MachabaKnoesen, OttoMeckel, MarianModiselle, MosheVorster, MarizaMarx, Sebastian2018-01-122018-01-122017-06Sathekge, M., Knoesen, O., Meckel, M. et al. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging (2017) 44: 1099-1100. https://doi.org/10.1007/s00259-017-3657-9.1619-7070 (print)1619-7089 (online)10.1007/s00259-017-3657-9http://hdl.handle.net/2263/63511Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with 177Lu-PSMA holds great promise as a safe treatment option in patients with metastasized castration-resistant prostate cancer (mCRPC) with appropriate selection. This approach, together with 68Ga-PSMA PET/CT, is an excellent example of theranostic nuclear medicine. However, more structured data have recently shown that despite a marked response to PSMARLT, some patients are refractory to 177Lu-radioligand therapy. Fortunately recent studies have demonstrated that targeted α-radiation therapy with 225Ac-PSMA can significantly benefit mCRPC patients. Similarly, 213Bi-DOTATOC may be able to break the radioresistance to β-emitters while simultaneously reducing haematological toxicity in patients with diffuse red marrow infiltration by neuroendocrine tumour.en© The Author(s) 2017. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/).177Lu-PSMATreatmentPatientsProstate-specific membrane antigen radioligand therapy (PSMA-RLT)Metastasized castration-resistant prostate cancer (mCRPC)Article